




Universal Biosensors

New Tools for the Enhanced Management of Chronic Disease

Based on a Proprietary,
Point of Care,
Electrochemical
Detection System



Important disclaimer

- This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. This presentation is not financial advice and has been prepared without taking into account the objectives, financial situation or needs of a particular person.
- Neither the Company, nor its officers or advisors or any other person warrants the accuracy of the analysis herein or guarantees the investment performance of the Company. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes.
- Under applicable United States securities laws all of the shares of our common stock are “restricted securities” as that term is defined in Rule 144 under the Securities Act of 1933, as amended (**Securities Act**). Restricted securities may be resold in the public market to United States persons as defined in Regulation S only if registered for resale or if they qualify for an exemption from registration under the Securities Act. We have not agreed to register any of our common stock for resale by security holders.
- The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this presentation include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this presentation are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations.
- The Company is subject to a number of risks. For a summary of key risks, refer to the Company’s most recent Form 10-K filed with the United States Securities and Exchange Commission.



Creating Shareholder Value

1	Creating a sustainable operating business
2	Pipeline of growth opportunities
3	Capitalising on emerging imperatives



- Our unique platform is validated
- Product developed for the biggest market
- Partnered with a market leader



- Pipeline of new products in development
- Assessing commercialisation strategies



- Capitalising on market trends:
 - Companion diagnostics
 - Evidence based medicine
 - Personalised medicine



Timeliness - A Key Missing Link



- Diagnosis and Monitoring relies largely on Central lab testing
- Automation has driven costs down in these settings
- Logistics and time are major drawbacks for this structure
- Improved and timely clinical decisions possible with robust Point Of Care Tests



Universal Biosensors

Initial Product – Blood Glucose Test

Sustainable
business

Pipeline
products

Emerging
trends

- Used as part of the treatment of Diabetes
- The market is large, established and still growing
- Our product has market leading attributes and our partnership with a market leader, Lifescan, means that we have a powerful offering
- This business is targeted to provide a stable and sustainable income base to Universal Biosensors. Total value will be determined by the commercial success of the products



Universal Biosensors

The In Vitro Diagnostics market


Sustainable business

Pipeline products


Emerging trends

The Global IVD market

2008 market size ~US\$40bn



IVD market segments (2005)



- The Glucose Monitoring market is the biggest and most mature segment of the IVD Point of Care (POC) industry
- Other POC markets are attractive growth opportunities for UBI, the total POC market expected to approach ~US\$18bn in size by 2012 growing at 10-12% pa.



Universal Biosensors

UBI and LifeScan (blood glucose/diabetes) – a strong relationship

Sustainable
business

Pipeline
products

Emerging
trends

- 2002 - Licence Agreement
- 2002 - Development and Research Agreement
- 2003 - Johnson and Johnson Development Corporation equity investment
- 2007 - Master Services and Supply Agreement (MSSA)
- 2008 - Fee for Service (scale up tasks)
- 2008 - Manufacturing Process Support Agreement (2008)
- 2009 - MSSA updated
- 2009 - Development and Research Agreement updated
- 2010 - UBI is preparing for a LifeScan launch of a first product



Universal Biosensors

UBI-LifeScan

Sustainable
business

Pipeline
products

Emerging
trends

- The Master Services and Supply Agreement:
 - Is an umbrella agreement permitting multiple products and services
 - UBI is a (non-exclusive) manufacturer of sensor strips
 - UBI anticipates developing other products for LifeScan
- Provides UBI revenue from:
 - Milestone payments for R&D success
 - Providing R&D services to LifeScan
 - Manufacturing Blood Glucose Strips
 - Service fee based on strips sold



Universal Biosensors

What to expect from this business

Sustainable
business

Pipeline
products

Emerging
trends

- Enhanced product could be registered as early as H2 2009
- UBI is production ready (strip manufacturing)
- LifeScan controls the timing of regulatory submissions and place and time of market entry
- UBI has given advice that it expects to have revenue in the first 12 months after Regulatory Clearance to Sell of \$A 25 million



Universal Biosensors


Flexible Platform Creates Many Opportunities

Sustainable business

Pipeline products

Emerging trends

Future development



A Unique Platform

Sustainable business


Pipeline products

Emerging trends

Disruptive Innovation Sophisticated, Simple, Unique

- Uses a dry, single use biosensor strip
- Measures biomarkers in a finger prick blood sample
- Uses a hand-held, battery powered, microprocessor controlled meter
- Lab-quality results
- Allows new Clinical Decision Rules to be formulated.....

The potential for better care at lower cost



- **SIMPLE TO USE**
- Use in MD offices, homes, pharmacy or on the ward
- By Patients, MDs, Specialists, Nurses / Nurse Aides, Pharmacists
- Similar to monitoring blood glucose levels



Universal Biosensors

Advantages of UBI Platform

Sustainable
business

Pipeline
products

Emerging
trends

✓	Easy to use	<ul style="list-style-type: none">▪ Derived from a product successfully used over 16bn times a year (blood glucose strip)<ul style="list-style-type: none">- Minimal user steps- Small finger stick sample
✓	Quantitative	<ul style="list-style-type: none">▪ Accurate and Precise<ul style="list-style-type: none">- Competitive with lab based tests
✓	Timely	<ul style="list-style-type: none">▪ Results produced quickly<ul style="list-style-type: none">- Tests expected to produce results in a matter of minutes
✓	Low cost	<ul style="list-style-type: none">▪ Simple design and automated manufacturing process dramatically reduces costs<ul style="list-style-type: none">- UBI can be the low cost producer
✓	Flexible	<ul style="list-style-type: none">▪ Platform can be adapted to develop tools for many other biomarkers▪ Attractive as:<ul style="list-style-type: none">- Part of companion diagnostics for Pharma- Timely intervention in a diagnostic setting

Product Pipeline

Sustainable business	APPLY CORE TECHNOLOGY: OPPOSED ELECTRODES, ALGORITHM, WEB BASED MANUFACTURE						PROTOTYPE	DEVELOPMENT CYCLE	PRODUCTION CAPABILITY/CAPACITY	MARKET REACH	MARKET LAUNCH	MARKET EXPANSION	
Pipeline products	Blood Glucose											Specification change 2/09	
Emerging trends	Enhanced Blood Glucose Product											2010	
	C-reactive Protein									CURRENTLY DESIGNING	NEGOTIATE Starting 2009	2011 →	
	Prothrombin Time									CURRENTLY DESIGNING	NEGOTIATE Starting 2009	2010	2011 →
	D-dimer									CURRENTLY DESIGNING	NEGOTIATE Starting 2009	2011	2012 →

Protected - Extensive Licensed and Owned IP

Sustainable
business

Pipeline
products

Emerging
trends

- 39 patent families covering products, manufacturing, core and peripheral technology
- 244 granted patents
- 171 pending applications
- 415 patents plus applications



Universal Biosensors

Current Healthcare Trends are Financially Unsustainable

Sustainable business

Pipeline products

Emerging trends

	Budget balance 2009E (% GDP)	% GDP on healthcare	Healthcare spending per capita	Growth in healthcare exp. per capita (pa.) (1990-2007)
US	(13.5%)	16.0%	US\$7,290	5.8%
France	(8.2%)	11.0%	US\$3,601	5.5%
Germany	(4.6%)	10.4%	US\$3,588	4.3%
Italy	(5.3%)	8.7%	US\$2,686	4.1%
Australia	(3.8%)	8.7%	US\$3,137	6.2%
UK	(14.4%)	8.4%	US\$2,992	6.9%
Japan	(7.4%)	8.1%	US\$2,581	5.3%

Sources: OECD, The Economist



Universal Biosensors

Current Healthcare Trends are Financially Unsustainable

Sustainable
business

Pipeline
products

Emerging
trends

Aging population

- Additional ~500m people expected to be aged over 60 in next 20 years
 - Increase in demand for healthcare
 - Reduction in Medicare contributions

Increased incidence of chronic disease

- +80% of people over 60 in the US have at least one chronic disease
- 50% have at least 2 Chronic diseases and 20% have diabetes
- Major chronic diseases include:
 - Diabetes, Cardiovascular disease, COPD, Cancer, Arthritis

Technology gap

- Major GP tools have not changed since the 1970's
- Most drugs only work in % of patients

SOMETHING HAS TO CHANGE!

Evidence Based Medicine

Sustainable
business

Pipeline
products

Emerging
trends

- Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients
- Healthcare systems are increasingly adopting evidence based medicine techniques to improve healthcare outcomes and remove unnecessary treatment costs from the system
- Accurate diagnostic tools are a key component of this transition and POC tests will become essential tools in a doctors office
- **UBI positioning:**
 - We are already developing CRP and D-dimer tests primarily for the doctors office and expect to develop more tests as needed and returns become apparent



Universal Biosensors


Personalised Medicine

Sustainable business

Pipeline products


Emerging trends

Existing healthcare model



- ✗ Costly and ineffective
- ✗ Many drugs are not effective
- ✗ Rx side effects are a leading cause of death in the US

Personalised medicine model



- ✓ Better patient outcomes
- ✓ Safer treatments
- ✓ Cost-effective healthcare

•Requires:

- Innovations in genetics
- Improved monitoring
- Patient self testing
- Improved IT systems

- **UBI positioning:**

- Tests in the pipeline for patient self-testing, more could come
- Evaluating and Developing technologies for potential applications in DNA/RNA (genetics) based testing

Companion Diagnostics

Sustainable
business

Pipeline
products


Emerging
trends

- Big Pharma have identified the attractiveness of combining simple point of care tests with their proprietary drugs - POC tests can drive increased drug penetration, reduce side effects and help select appropriate patients for the treatment
- Provides potential for new partnerships in the sector
 - significant synergies to share between drug and diagnostic companies
- **Universal Biosensors positioning:**
 - Assessing the attractiveness of companion diagnostic partnerships for pipeline products such as our CRP test
 - Possibility of partnering with Pharma companies to develop companion tests for new and existing products



Universal Biosensors

Complex made Simple with the Power of the Technology



Powerful algorithms

Powerful breadth

Powerful manufacturing

Whole blood
finger stick
sample

Accurate for the
individual


Comprehensive
Care

Robust, Reliable,
Affordable

Helps better meet
the needs of patients



Deals and Corporate Activity



Beauty is

In the Eye of
the Beholder



Universal Biosensors

Corporate Summary

Summary

Number of Shares on issue 157,038,558

Market capitalization at 9 Oct 2009 ~A\$227.7 million

Number of Options on issue 8,443,528

Cash (at Sept 30, 2009) ~A\$17.9 million

Board of Directors

Mark Morrisson (CEO), Andrew Denver (Chairman), Colin Adam,
Denis Hanley, Andrew Jane, Charles Kiefel, Jane Wilson



Universal Biosensors